Investment in Equities.

6 Months Ended

May 31, 2023

Equity Method Investments and Joint Ventures [Abstract]

Investment in Equities.

Note 3 – Investment in Equities.

The following equity investments that have a readily determinable fair value are measured using ASC Topic 820, discussed above. The following equities without a readily determinable fair value use the measurement alternative of ASC Topic 321 and are measured at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined, for the identical or a similar investment of the same issuer.

Description	How Acquired	Readily Determinable Fair Value	Cost		Current Changes			Cumulative Impairments		Prior Cumulative Adjust.			May 31, 2023 Bal. Sheet Value
38,441,500 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com)	Origination Fees	No	$	0	$	0		$	0	$	0		$	0
4,135,614 shares of restricted stock in Patient Access Solutions, Inc. (“PASO” on OTCMarkets.com)	Consulting Income	No	$	0	$	0		$	0	$	0		$	0
222 shares of unrestricted stock in Canibiola, Inc. (“CANB” on OTCMarkets.com)	Consulting Income	Yes	$	0	$	(18	)	$	0	$	140		$	122
11,960,006 shares of unrestricted common stock in BHPA, Inc (“BHPA” on OTCMarkets.com)	Consulting Income	Yes	$	0	$	(29,900	)	$	0	$	149,500		$	119,600
6,000 shares of Gabelli Equity Trust Inc. stock	Purchase	Yes	$	35,572		(2,215	)		0		(1,137	)	$	32,220
2,500 shares of Etao Intl. Co. Ltd. Common stock	Purchase	Yes	$	3,767		(2,617	)		0		-		$	1,150
Totals			$	39,339	$	(34,750	)	$	0	$	148,503		$	153,092